145 related articles for article (PubMed ID: 38362648)
1. Adherence to prescription proton pump inhibitor therapy amongst individuals diagnosed with Barrett's esophagus.
Gaber CE; Abdelaziz AI; Sarker J; Lund JL; Dellon ES; Cotton CC; Eluri S; Shaheen NJ
Pharmacoepidemiol Drug Saf; 2024 Feb; 33(2):e5760. PubMed ID: 38362648
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
4. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
5. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
6. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
7. The Role of Acid Suppression in Barrett's Esophagus.
Elias PS; Castell DO
Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
[TBL] [Abstract][Full Text] [Related]
8. Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus.
Shah SL; Dunbar K
Curr Gastroenterol Rep; 2023 Dec; 25(12):374-379. PubMed ID: 37940812
[TBL] [Abstract][Full Text] [Related]
9. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
10. Current Status of Chemoprevention in Barrett's Esophagus.
Moayyedi P; El-Serag HB
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
[TBL] [Abstract][Full Text] [Related]
11. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis.
Hu Q; Sun TT; Hong J; Fang JY; Xiong H; Meltzer SJ
PLoS One; 2017; 12(1):e0169691. PubMed ID: 28072858
[TBL] [Abstract][Full Text] [Related]
12. Management of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma.
Cotton CC; Eluri S; Shaheen NJ
Gastroenterol Clin North Am; 2022 Sep; 51(3):485-500. PubMed ID: 36153106
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
Yao H; Wang L; Li H; Xu S; Bai Z; Wu Y; Chen H; Goyal H; Qi X
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):79-88. PubMed ID: 34806503
[TBL] [Abstract][Full Text] [Related]
14. Transepithelial leak in Barrett's esophagus patients: the role of proton pump inhibitors.
Farrell C; Morgan M; Tully O; Wolov K; Kearney K; Ngo B; Mercogliano G; Thornton JJ; Valenzano MC; Mullin JM
World J Gastroenterol; 2012 Jun; 18(22):2793-7. PubMed ID: 22719187
[TBL] [Abstract][Full Text] [Related]
15. Medication usage and the risk of neoplasia in patients with Barrett's esophagus.
Nguyen DM; El-Serag HB; Henderson L; Stein D; Bhattacharyya A; Sampliner RE
Clin Gastroenterol Hepatol; 2009 Dec; 7(12):1299-304. PubMed ID: 19523538
[TBL] [Abstract][Full Text] [Related]
16. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
17. Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?
Spechler SJ
Dig Dis; 2014; 32(1-2):156-63. PubMed ID: 24603402
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
[TBL] [Abstract][Full Text] [Related]
19. Barrett's esophagus: proton pump inhibitors and chemoprevention II.
Richter JE; Penagini R; Tenca A; Pohl D; Dvorak K; Goldman A; Savarino E; Zentilin P; Savarino V; Watson JT; Wong RK; Pace F; Casini V; Peura DA; Herzig SJ; Kamiya T; Pelosini I; Scarpignato C; Armstrong D; DeVault KR; Bechi P; Taddei A; Freschi G; Ringressi MN; Degli'Innocenti DR; Castiglione F; Masini E; Hunt RH
Ann N Y Acad Sci; 2011 Sep; 1232():114-39. PubMed ID: 21950810
[TBL] [Abstract][Full Text] [Related]
20. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]